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Abstract:
Background: EBV infection is thought to play a central role in the 
development of Multiple Sclerosis (MS). If causal, it represents a target 
for interventions to reduce MS risk. 
Objectives: To examine the evidence for interaction between EBV and 
other risk factors, and explore mechanisms via which EBV infection may 
influence MS risk. 
Methods: Pubmed was searched using the terms “multiple sclerosis” AND 
“Epstein Barr virus”, “multiple sclerosis” AND EBV, “clinically isolated 
syndrome” AND “Epstein Barr virus” and “clinically isolated syndrome” 
AND EBV. All abstracts were reviewed for possible inclusion. 
Results: 262 full-text papers were reviewed.  There was evidence of 
interaction on the additive scale between anti-EBV antibody titre and 
HLA genotype (AP 0.48, p<1x10-4; RERI 3.84, p<5x10-3; S 1.85, 
p=0.23). Previous IM was associated with increased OR of MS in HLA-
DRB1*1501 positive but not HLA-DRB1*1501 negative persons. Smoking 
was associated with a greater risk of MS in those with high anti-EBV 
antibodies (OR 2.76) but not low anti-EBV antibodies (OR 1.16).  No 
interaction between EBV and risk factors was found on a multiplicative 
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scale. 
Conclusions:  EBV appears to interact with at least some established MS 
risk factors. The mechanism via which EBV influences MS risk remains 
unknown.  
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Abstract
Background: EBV infection is thought to play a central role in the development of Multiple 
Sclerosis (MS). If causal, it represents a target for interventions to reduce MS risk.
Objective: To examine the evidence for interaction between EBV and other risk factors, and 
explore mechanisms via which EBV infection may influence MS risk.
Methods: Pubmed was searched using the terms “multiple sclerosis” AND “Epstein Barr 
virus”, “multiple sclerosis” AND EBV, “clinically isolated syndrome” AND “Epstein Barr 
virus” and “clinically isolated syndrome” AND EBV. All abstracts were reviewed for 
possible inclusion.
Results: 262 full-text papers were reviewed.  There was evidence of interaction on the 
additive scale between anti-EBV antibody titre and HLA genotype (AP 0.49, p<1x10-4). 
Previous Infectious Mononucleosis (IM) was associated with increased OR of MS in HLA-
DRB1*1501 positive but not HLA-DRB1*1501 negative persons. Smoking was associated 
with a greater risk of MS in those with high anti-EBV antibodies (OR 2.76) but not low anti-
EBV antibodies (OR 1.16).  No interaction between EBV and risk factors was found on a 
multiplicative scale. 
Conclusions:  EBV appears to interact with at least some established MS risk factors. The 
mechanism via which EBV influences MS risk remains unknown.  
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Introduction
Multiple sclerosis (MS) is thought to arise as the result of acquired environmental risk in a 
genetically susceptible population1–4. Environmental risk factors for MS include Epstein-Barr 
Virus (EBV) infection, smoking, obesity during adolescence, and low serum vitamin D2. 
Understanding how environmental risk factors interact with each other and with genotype is 
crucial to developing targeted preventative strategies. 
We set out to update and extend our understanding of the interaction between EBV and other 
MS risk factors. To our knowledge, there has been no previous attempt to integrate all data 
related to how EBV interacts with other MS risk factors. One meta-analysis has examined the 
potential interaction between EBV serostatus and HLA in MS; other previous meta-analyses 
have not studied risk factor interaction5–8. 
Interaction can be defined as the situation in which the relationship between exposure and 
outcome depends, in some way, on the presence or value of some other exposure. It is 
important to distinguish between biological interaction – the claim that there are physical, 
mechanistic relationships between the exposures, and statistical interaction - a directly 
estimable property from observed data on the probability of the outcome given different 
combinations of exposures. Inferring biological interaction from statistical interaction is not 
trivial, and requires additional mechanistic evidence to show biological plausibility. 
Studying interaction(s) in the pathogenesis of MS is important for several reasons: it can 
identify individuals in whom specific exposures are of particular importance, which has 
implications for who to target with prevention studies, and it sheds light on disease 
pathogenesis by identifying overlapping causal pathways to disease. For instance, the 
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observation that obesity interacts with HLA genotype suggests not only that anti-obesity 
measures are particularly important in individuals with high-risk HLA haplotypes, but also 
argues for the effect of obesity on MS risk being immune-mediated.
Statistical interaction can be conceived of on two scales: additive interaction (or ‘departure 
from additivity’), where the risk of the outcome exceeds the sum of risk conferred by each 
exposure; or multiplicative interaction, where the risk of the outcome exceeds the product of 
the relative risks for each exposure. For public health purposes, e.g. deciding which 
subgroups of individuals will benefit more from a treatment or vaccine, additive interaction is 
the more relevant measure as it captures absolute benefit (i.e. total number of diseases 
prevented), which can be missed on the multiplicative scale if baseline risks in the two groups 
are different38.  
Nested case-control studies using large health repositories9,10 have made a major contribution 
to epidemiological evidence supporting a causal relationship between EBV and MS. 
However, the high rate of EBV seropositivity in the general population argues against EBV 
seropositivity alone being a sufficient factor for causing MS7. The prevalence of MS in EBV-
negative individuals is virtually zero when highly sensitive techniques are used to assess 
EBV serostatus11,12. Symptomatic EBV5–7,13–15 infection (IM) confers a greater risk of MS 
than asymptomatic EBV carriage. 
 
Population-based epidemiological studies indicate that EBV infection and other 
environmental risk factors may interact with genotype in the pathogenesis of MS 16. To our 
knowledge there have been no previous attempts to systematically pool these estimates.  In 
this systematic review and meta-analysis, we examine all the available evidence for EBV 
interaction with other MS risk factors (both in terms of EBV serostatus and IM) using both 
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multiplicative and additive models for interaction. We also examine the reported relationship 
between EBV and MS, and pool evidence around the relationship between active EBV 
turnover (as measured by PCR) and MS. Finally, we provide a narrative systematic review of 
the literature around MS and EBV. 
 
Methods
 Search strategy
Pubmed was searched using the terms “multiple sclerosis” AND “Epstein Barr virus”, 
“multiple sclerosis” AND EBV, “clinically isolated syndrome” AND “Epstein Barr virus” 
and “clinically isolated syndrome” AND EBV. Search dates were 1950-present. The most 
recent search was performed on 22nd December 2018.
 
All abstracts were reviewed for possible inclusion. Studies for use in the meta-analysis were 
screened according to the following criteria: containing both MS and control group, and using 
either standard techniques to establish EBV serostatus, history of IM, or PCR. Where these 
criteria were met, the full text was retrieved.
 
Following this, relevant studies were reviewed and data extracted. Where full text was not 
available, the authors were contacted to provide the article. Where it was judged unclear as to 
whether data within selected papers met the inclusion criteria (details of inclusion criteria for 
each analysis are given in the results section), a second co-author independently reviewed the 
paper, and a consensus decision was reached. The quality of data were assessed by recording 
the reported security of MS diagnosis (no clear criteria and/or self-reported vs. explicit 
criteria used for diagnosis, the gold standard), and technique for assessing EBV (ELISA vs. 
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immunofluorescence, the gold standard).  All references of retrieved review and/or meta-
analyses were reviewed for additional articles not captured during the original search.  
Technical differences between study design may introduce bias and limit the validity of 
pooled effect estimates. Such differences included: differences in clinical criteria for MS 
diagnosis, differences in method of IM diagnosis (clinical, recall questionnaire, serological), 
differences in laboratory techniques (e.g. immunofluorescence vs ELISA), differences in 
HLA genotyping (molecular typing vs SNP imputation), and difference in the quantification 
of smoking exposure (cotinine vs questionnaire). To overcome these difficulties, we 
performed subgroup analyses where appropriate to stratify by these potential sources of 
heterogeneity (e.g. by method of HLA genotyping).
All included full text papers were assigned to analyses covered by this review - EBV 
interaction with other MS risk factors, serology and MS risk, infectious mononucleosis and 
MS risk, EBV DNA detection and MS, papers covering possible mechanisms of EBV 
contribution to MS risk, and papers examining the relationship between immune response to 
EBV and MS-related clinical or MRI outcomes. A single paper could be assigned to any 
number of analyses, and each analysis/review was performed independently of all others.
 
Statistical methods
Meta-analyses were conducted in R v3.6.1 using the ‘meta’ package based on reported data. 
Odds ratios (ORs) were calculated using a Mantel-Haenszel random effects model with a 
continuity correction. Bias was quantified using the efficient score (a linear regression of 
funnel plot asymmetry)17. For interaction studies, odds ratios were pooled using inverse 
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variance-weighted meta-analysis. Where data were available, unadjusted odds ratios were 
calculated.
 
For interaction studies, the highest and lowest exposure groups were used - e.g. where 
Epstein-Barr Virus Nuclear Antigen (EBNA) titres were divided into quartiles, we took the 
lowest and the highest groups as ‘EBNA lo’ and ‘EBNA hi’ respectively. Interaction was 
assessed by calculating 4 measures of interaction: where the numbers of cases and controls in 
each risk factor group were presented, the Attributable Proportion due to interaction (AP), the 
relative excess risk due to interaction (RERI), the Synergy index (S), and multiplicative 
interaction18,19 were calculated. For two risk factors of interest, e.g. smoking and HLA status, 
if OR11 indicates the Odds Ratio for MS in individuals exposed to both risk factors, OR10 the 
OR for HLA+ non-smokers and OR01 that for HLA- smokers:
RERI = OR11 – OR10 – OR01 + 1
 
S = OR11 – 1 / ( (OR10 – 1) – (OR01 – 1) )
 
AP = (OR11 – OR10 – OR01 + 1)/ OR11
 
In the absence of interaction, RERI and AP will be 0, and S will be 1. Measures of departure 
from additivity (AP, RERI, and S) were calculated using the indicator variable method 
described previously19 in R v 3.6.1 . As standard errors can only be computed for the natural 
log of the synergy index, we have presented this measure as log(Synergy Index)+/- 95% 
confidence intervals. A null effect (no interaction) would give a log(Synergy Index) of 0 
(ln(1) = 0). Multiplicative interaction was calculated by performing logistic regression with 
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an interaction term. If OR represents the Odds Ratio for MS, x1 one risk factor, x2 the second 
risk factor, and x1x2 the product (interaction) term, then:
 
Ln(OR) = b0 + b1x1 + b2x2 + b3x1x2
 
The exponent of the interaction term coefficient b3 represents the multiplicative interaction 
between the two risk factors. For these analyses, the regression model did not adjust for 
variables other than the two risk factors in question. Standard errors were calculated for 
measures of additive interaction using the delta method18. Standard errors for the 
multiplicative interaction were calculated from the output of the logistic regression model. 
Meta-analysis of interaction terms was performed using the inverse variance method with a 
random effects model.
 
Data and code availability statement
This work was performed using published data. All data sources are listed in the references 
and supplementary references. All R code used for the analysis is available on Github 
(https://github.com/benjacobs123456/EBV_meta_analysis/blob/master/analysis.R).
 
Results
A total of 632 references were retrieved using the search terms  “multiple sclerosis” AND 
“Epstein Barr virus”, and  “multiple sclerosis” AND EBV. “Multiple sclerosis” AND EBV, 
“clinically isolated syndrome” retrieved 22 references, all of which had been captured in the 
previous search. “Clinically isolated syndrome” AND EBV retrieved a further 17 references, 
again all of which had been previously captured. Review of all references of meta-analyses 
and systematic reviews provided 6 unique new results. 370 results were discarded following 
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review of abstracts for reasons including pre-selecting EBV positive patients only, having no 
control group, validation studies of new methods for EBV serology. 262 full text papers were 
reviewed and included as summarized in Fig. 1.
 
EBNA titre interaction with HLA-DRB1*1501 in MS
10 papers20–28 were included for this analysis. All but one paper presented HLA-DRB1*1501 
homo- and heterozygotes pooled into a single group (“HLA positive”), and so this grouping 
was used in the analysis. Where EBNA titres were divided into quartiles, we took the highest 
and lower quartiles to represent ‘high’ and ‘low’ titres respectively. One paper26 was 
excluded due to overlapping participants with another paper22.
 
The odds ratio (OR) of MS in individuals with high anti-EBV antibody titres is increased in 
HLA-DRB1*1501 positive (OR 7.90, 95% CI 4.11 – 15.21) compared to HLA-DRB1*1501 
negative individuals (OR 3.04, 95% CI 1.99 – 4.63, Fig. 2, Table 1). Studies differed in their 
method of HLA genotyping. Restricting the analysis to studies using tagging SNPs 
(rs3135005 or rs9271366) did not significantly alter the results (Fig. S1). Restricting the 
analysis to studies using PCR-based methods yielded a similar result (Fig. S1). 
 
Individual-level data were available for five studies. We estimated the degree of interaction 
between HLA status and EBNA titre by calculating the AP, Synergy Index, RERI, and the 
degree of multiplicative interaction as described above. There was evidence of significant 
interaction between EBNA titre and HLA genotype on the additive scale in terms of the AP 
and RERI (AP 0.48, p<1x10-4; RERI 3.84, p<5x10-3; S 1.68, p=0.06). There was no evidence 
of interaction on the multiplicative scale (𝛽 1.27, p=0.74) (Fig. 2, Table 1). Subgroup 
analyses based on method of HLA genotyping are presented in table S1. 
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Infectious Mononucleosis interaction with HLA-DRB1*1501 in MS
To estimate the prevalence of prior IM among controls and people with MS, we reviewed 32 
full text papers, of which 19 met the inclusion criteria (supplementary references). Inclusion 
criteria were MS and control group, clearly stated methods for obtaining a previous history of 
IM, and no selection on the basis of reported history of IM. Previous Infectious 
Mononucleosis (IM) was more common in people with MS (OR 2.00, 95% CI 1.80 to 2.20, 
p< 0.0001, Fig. 3). There was significant heterogeneity (Q=31.0, p=0.03) but no evidence of 
publication bias (p=0.62, Fig. 3). This effect persisted after restricting studies to those using 
criteria-defined MS (OR 1.94, 95% CI 1.81 to 2.07, Fig. 3).
Four papers examined the potential interaction between previous infectious mononucleosis 
and HLA-DRB1*1501 status and MS20,22,28,29. Again, homo- and heterozygote status was 
pooled into “HLA positive”. A history of IM is associated with increased OR of MS in HLA-
DRB1*1501 positive individuals (OR 5.11 95% CI 2.00-13.03; p<1x10-3) but not in HLA-
DRB1*1501 negative individuals (OR 1.22 95% CI 0.33-4.48; p=0.77, Fig. 3, Table 2). 
Three studies had individual-level data available. There was no significant interaction on the 
additive or multiplicative scales between HLA status and IM in the meta-analysis of 3 studies 
with individual-level data available (Fig. 3, Table 2). Subgroup analysis by method of HLA 
genotyping did not significantly alter the results (Fig. S2). 
EBV interaction with smoking in MS
5 papers studied the potential interaction between smoking status and anti-EBV antibody 
titre25,26,28,30,31. Three studies stratified smoke exposure as ever vs never smokers, one study 
used second-hand smoke exposure as a variable, and one study distinguished active from 
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inactive smoking using serum cotinine levels. Smoking is associated with a greater risk of 
MS in those with high anti-EBV antibodies (OR 2.76 95%CI 2.13-3.59; p<1x10-5) but not in 
those with low anti-EBV antibodies (OR 1.16 95%CI 0.95-1.42; p=0.15). There was no 
significant interaction on the multiplicative or additive scales in the meta-analysis of the four 
eligible studies (Fig. 4, Table 3). Exclusion of either the study using second-hand smoke as 
the exposure or using serum cotinine as a proxy for smoking did not significantly affect the 
results (Table S2). 
 EBV interaction with vitamin D in MS risk
Only 2 studies presented data on both EBV and vitamin D in MS3233. One of these studies 
looked at vitamin D levels in people with established MS32, and the other in samples taken 
both prior to and following MS onset, with multiple, variable sampling points per 
participant33. One study applied a correction to vitamin D levels for month of sampling33, the 
other did not32. In addition, one study using a single EBNA epitope33, whereas the other 
looked at specific EBNA-1 domains32. Neither study demonstrated any interaction between 
vitamin D level and anti-EBNA titre, however for the reasons above they were not pooled.
EBV interaction with obesity in MS risk
 Only one study examined the potential interaction between EBV and obesity in risk of MS34. 
This study demonstrated a striking potential interaction on an additive scale with an 
attributable proportion due to interaction of 0.8 (95%CI 0.6-1.0) in the incident study, and in 
the prevalent study an attributable proportion due to interaction of 0.7 (95%CI 0.5-1.0)34.
 
EBV seropositivity and MS
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56 papers were included in the final analysis for this analysis (supplementary references). 
Inclusion criteria were MS and control group, no pre-selection of groups based on EBV 
serostatus and history of IM, EBV serology measured using clearly defined methods. Reasons 
for exclusion included not having a control group and pre-selecting EBV positive patients. 
Studies were separated into those examining adult vs. paediatric MS populations given the 
reported differences in seroprevalence between the two groups. Following an assessment of 
data quality, validatory analyses were performed limiting studies to those deemed to be of 
high quality. Seropositivity for EBV was calculated by pooling results from studies which 
reported seropositivity to either EBNA, VCA, or both. Where both were reported, the EBNA 
data were used. Studies using different EBNA1 and EBNA2 epitopes were pooled for all 
analysis.
 
EBV seropositivity was significantly more common among people with MS (adults and 
children) than controls (OR(EBV seropositivity | MS status) OR 3.9092, 95% CI 3.0810 to 4.9396 ,p< 
0.0001, Fig. 5). There was evidence of significant heterogeneity (Q=150.5131.53, p<1x10-4) 
and publication bias (p<0.05). Overall, 6623/74216868/7459 people with MS were EBV 
seropositive (89.292.1 %) compared with 6277/81926231/8266 EBV seropositive control 
subjects (76.681.4%). 
EBV seropositivity was more prevalent among adults with MS compared to controls (OR(EBV 
seropositivity | MS status) 3.4783, 95% CI 2.6587 to 4.535.10, p< 0.0001 ). There was substantial 
heterogeneity between studies (Q=115111.3 p<x10-4) and evidence of publication bias 
(p=0.012), with studies demonstrating a relationship between EBV infection and MS more 
likely to be published. Overall, 5950/66456225/6700 adults with MS were EBV seropositive 
(89.592.9%) compared with 5796/72076220/7268 adult control subjects (80.485.6%).  EBV 
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seropositivity was more common among children with MS or CIS than controls (OR(EBV 
seropositivity | MS status) 5.404.30, 95% CI 4.143.33 to 7.035.54, p< 0.0001). There was no evidence 
of heterogeneity (Q=9.008.1, p=0.4452) and no evidence of publication bias (p=0.75). 
Overall, 673/776643/759 children with MS were EBV seropositive (8684.7%) compared with 
481/985511/998 control subjects (48.851.2%).
 
IgG reactivity to the Viral Capsid Antigen (VCA) was more prevalent among adults with MS 
(OR 3.23, 95% CI 2.05 to 5.10, p<1x10-4, data not shown). 
There was substantial heterogeneity between studies (Q=53.3, p=0.0002) and no evidence of 
publication bias (p=0.12). Reactivity to the EBNA antigen was again more prevalent among 
people with MS compared to controls (OR 3.63, 95% CI 2.69 to 4.89, p<1x10-4, data not 
shown). There was substantial heterogeneity between studies (Q=73.2, p<1x10-4) with 
evidence of publication bias in these studies (p<0.003). 
 
The increased seroprevalence of EBV infection in people with MS/CIS remained significant 
when restricting included studies to those using the more sensitive technique of 
immunofluorescence (rather than enzyme-linked immunosorbent assay) to detect EBV 
antibodies (OR 4.6362, 95% CI 2.24 to 9.5753). Similarly, when restricting included studies 
to those which used explicit diagnostic criteria to define MS, this effect remained significant 
(OR 3.7247, 95% CI 2.8464 to 4.8856).
   
EBV DNA detectable by PCR. 
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31 full text papers were reviewed and 23 included in the analysis (supplementary references). 
8 papers studied EBV DNA in CSF, 3 in whole blood, 7 in peripheral blood mononuclear cells, 
4 in plasma/serum and 1 in saliva. The EBNA gene was the most commonly used for EBV 
detection (9 studies), with BAM used in 4 studies, VCA in 3 studies, and LMP in 2 studies. 
EBV DNA was detectable in whole blood/PBMC more often in people with MS versus 
controls  (n = 1853, 9 studies, OR 3.48, 95% CI 1.7360-6.9659, p<5x10-4). There was evidence 
of significant heterogeneity (Q=48.94, p<1x10-4) but no evidence of publication bias (p=0.78). 
Detection of EBV DNA did not differ between MS and control serum/plasma samples (n = 
607, OR 1.81, 95% CI 0.77-4.26; p=0.18) or CSF (n = 802, OR 1.74, 95% CI 0.97-3.12, p = 
0.062).
 
Discussion and conclusions
 There is a considerable body of epidemiological evidence implicating EBV in the 
pathogenesis of MS. EBV infection appears to be a necessary but not sufficient requirement 
for developing MS, EBV seroprevalence is higher among people with MS, symptomatic EBV 
infection (IM) is more prevalent among people with MS, and HLA-DRB1*1501 genotype 
modifies the effect of anti-EBV antibody titre on MS risk.  
 
In our meta-analysis of interaction between EBV and other risk factors, we demonstrate 
evidence for supra-additive interaction between EBNA titre and HLA status in determining 
risk. The absence of strong evidence for interaction between EBV and other risk factors in 
our analysis demonstrates the importance of using multiple measures of interaction (AP, 
RERI, Synergy Index, and multiplicative interaction) to avoid the risk of type 1 error. 
However, the small number of studies suitable for our analysis of interaction and the presence 
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of substantial heterogeneity between studies limits the power of this meta-analysis, and 
therefore conclusions about interaction should be drawn cautiously from these results.
We observed significant heterogeneity in the HLA-EBNA and HLA-IM analyses. Although 
we overcome some of this heterogeneity by using random-effects meta-analysis, we 
acknowledge that this heterogeneity not only questions the validity of combining such 
studies, but also is a likely source of imprecision that may bias the estimates of interaction. 
Sources of such heterogeneity include differences in EBNA antigen and detection method, 
different EBNA titre distributions within studies, different methods of HLA genotyping, 
different distributions of HLA alleles within the populations studies, different methods of IM 
diagnosis, and other differences between the populations studied such as age, gender split, 
and exposure to other risk factors which may confound the associations. We have attempted 
to reduce the heterogeneity in these estimates by performing various pre-specified sensitivity 
analyses (e.g. by method of HLA genotyping). Reassuringly, these sensitivity analyses 
aligned with the primary analyses. Nonetheless, we emphasise that our results alone should 
not be overinterpreted due to the substantial heterogeneity between studies. 
Another important limitation of our study is that, in order to calculate standard errors for 
measures of additive interaction (AP, RERI, and Synergy Index), raw data are required 
regarding the number of participants in each stratum of exposure. To adjust for confounding, 
the number of participants in each stratum of the confounder must also be known. As these 
data are not publicly available, our estimates of interaction are calculated without adjustment 
for confounding, which clearly has the potential to bias the study-level and meta-analysed 
estimates of interaction. It is possible to calculate measures of interaction (but not their 
standard errors) from the output of multivariate logistic regression models (which are 
adjusted for confounding): although the number of included studies was greater in these 
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analyses (table 1-3), these estimates did not differ dramatically from the measures of 
interaction calculated from studies with raw data available (RERI HLA-EBNA: 1.94; RERI 
HLA-IM 2.14; RERI Smoking-EBNA 0.29). These results suggest that our analyses have 
limited power to detect a true interaction, but do not suggest that our results are biased. 
 
The mechanism via which EBV exerts this increased risk remains unknown, and our 
systematic review of the literature highlights a multitude of potential biological mechanisms 
that have been both demonstrated, replicated, and importantly not replicated. It seems likely 
that the route via which EBV exerts its effect lies in complex interactions between EBV and 
the host genome, the precise mechanisms of which remain to be elucidated. 
Large prospective cohort and case-control studies have provided strong evidence implicating 
IM in the pathogenesis of MS17. Although formal analysis of interaction did not reveal 
interaction between IM and HLA, the OR for MS differed strikingly between IM+HLA- 
individuals (OR 1.22) and IM+HLA+ individuals (OR 5.11). These observations suggest that 
IM may be a more significant predictor of MS risk in HLA DRB1*1501 carriers. Practically, 
this hypothesis would have important implications for targeted MS prevention, as it would 
suggest that IM prevention (e.g. with an EBV vaccine2) should be targeted to DRB1*1501 
carriers to maximise benefit. Our data alone do not provide a sufficiently strong case for this 
strategy, but do add to the argument that this approach may be effective.
Our results for the seroprevalence of EBV among people with MS are consistent with the 
previously published meta-analysis, which reported ORs of 4.47 (95%CI 3.26-6.11) and 4.51 
(95%CI 2.84-7.16) for EBNA and VCA respectively. Our estimates of 3.63 (95% CI 2.69 to 
4.89) and 3.23 (95% CI 2.05 to 5.10) are more conservative, likely reflecting new, larger 
studies with smaller effect sizes and our different inclusion criteria7. Similarly, our estimates 
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of measures of interaction between EBNA titre, HLA status, and MS risk are similar, though 
not identical, to the published meta-analysis estimates35. The previous study used fixed-
effects meta-analysis as opposed to random-effects (which we use here) to pool estimates of 
interaction, but other reasons for this discrepancy are not clear.
Despite the evidence above, not all epidemiological aspects of MS can be explained by EBV 
infection. The relatively short latency between putative infection and subsequent MS seen in 
the Faroe epidemics, and the decreasing risk in migrants moving from high- to low-risk areas 
cannot be explained purely by EBV infection - the fact remains that MS is overwhelmingly 
likely to be the result of multiple environmental risk modifiers. However, evidence for EBV 
infection as an obligate step in MS development is increasing, and with vaccination on the 
horizon as a potential preventive intervention, cannot be ignored. 
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Table 1: odds ratios and 95% confidence intervals for MS in each stratum of EBNA titre and 
HLA genotype. In the top half of the table, odds ratios are derived from meta-analysis of all 
studies. In the bottom half, estimates of additive and multiplicative interaction are shown 
with their standard errors. These estimates are derived from only those studies with 
individual-level data (i.e. number of participants in each stratum) available.
 HLA- HLA+
EBNA lo (OR; 95% CI) 1 (reference) 2.90 (2.03 – 4.14)
EBNA hi (OR; 95% CI) 3.04 (1.99 – 4.63) 7.90 (4.11 – 15.21)
 Estimate SE (p)
AP 0.49 0.12 (3.09E-05)
RERI 3.84 1.35 (0.004)
Log(Synergy index) 0.52 0.28 (0.059)
Multiplicative interaction 1.27 0.81 (0.739)
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Table 2: odds ratios and 95% confidence intervals for MS in each stratum of IM and HLA 
genotype. In the top half of the table, odds ratios are derived from meta-analysis of all 
studies. In the bottom half, estimates of additive and multiplicative interaction are shown 
with their standard errors. These estimates are derived from only those studies with 
individual-level data (i.e. number of participants in each stratum) available.
 HLA- HLA+
IM- (OR; 95% CI) 1 (reference) 2.75 (2.07 – 3.64)
IM+ (OR; 95% CI) 1.22 (0.33 – 4.48) 5.11 (2.00 – 13.03)
 Estimate SE (p)
AP 0.29 0.15 (0.053)
RERI 0.48 0.97 (0.624)
Log(Synergy index) 0.48 0.29 (0.100)
Multiplicative interaction 1.71 0.93 (0.443)
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Table 3: odds ratios and 95% confidence intervals for MS in each stratum of EBNA titre and 
smoking status. In the top half of the table, odds ratios are derived from meta-analysis of all 
studies. In the bottom half, estimates of additive and multiplicative interaction are shown 
with their standard errors. These estimates are derived from only those studies with 
individual-level data (i.e. number of participants in each stratum) available.
 Smoking- Smoking+
EBNA lo (OR; 95% CI) 1 (reference) 1.16 (0.95 – 1.42)
EBNA hi (OR; 95% CI) 2.31 (1.61-3.32) 2.76 (2.13 – 3.59)
 Estimate SE (p)
AP 0.19 0.13 (0.125)
RERI 0.42 0.47 (0.348)
Log(Synergy index) 0.22 0.21 (0.280)
Multiplicative interaction 1.38 0.79 (0.629)
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Figure legends
 
Figure 1: PRISMA flow charts with details of publications retrieved via searches, abstracts 
screened, full text articles assessed and used in analyses
 
Figure 2: (a) Forest plot demonstrating ORMS for HLA+EBNAhi persons. (b) Forest plot 
demonstrating ORMS for HLA+EBNAlo persons. (c) Forest plot demonstrating ORMS for 
HLA-EBNAhi persons. (d) Bar chart demonstrating evidence of interaction between HLA-
DRB1*1501 genotype and EBNA antibody titre on an additive, but not multiplicative scale. 
The dotted line represents the null (OR = 1). (e) - (h) Forest plots demonstrating estimates of 
interaction - AP, RERI, Synergy index, and multiplicative interaction respectively - for 
studies with individual-level data available. MIT: Multiplicative interaction term. The 
reference group (with OR = 1) is HLA-EBNAlo  individuals for all panels. 
Figure 3: (a) Forest plot demonstrating ORMS for HLA+IM+ persons. (b) Forest plot 
demonstrating ORMS for HLA+IM- persons. (c) Forest plot demonstrating ORMS for HLA-IM+ 
persons. (d) Bar chart demonstrating lack of evidence of interaction between HLA-
DRB1*1501 genotype and prior IM on an additive, but not multiplicative scale. The dotted 
line represents the null (OR = 1). (e) - (h) Forest plots demonstrating estimates of interaction 
- AP, RERI, Synergy index, and multiplicative interaction respectively - for studies with 
individual-level data available. MIT: Multiplicative interaction term. The reference group 
(with OR = 1) is HLA-IM-  individuals for all panels. 
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Figure 4: (a) Forest plot demonstrating ORMS for EBNAhiSmoking+ persons. (b) Forest plot 
demonstrating ORMS for EBNAhiSmoking- persons. (c) Forest plot demonstrating ORMS for 
EBNA-Smoking+ persons. (d) Bar chart demonstrating lack of evidence of interaction 
between smoking status and EBNA titre on an additive, but not multiplicative scale. (e) - (h) 
Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and 
multiplicative interaction respectively - for studies with individual-level data available. MIT: 
Multiplicative interaction term. The reference group (with OR = 1) is HLA-Smoking-  
individuals for all panels. 
Figure 5: (a) Combined forest plot with meta-analysis of EBV seropositivity in children and 
adults with MS. (b) Funnel plot demonstrating evidence of publication bias in publications 
examining EBV seropositivity and MS
 
Figure 6: (a) Forest plot of studies examining the relationship between previous infectious 
mononucleosis  and MS. (b) Funnel plot demonstrating no clear evidence of publication bias 
in these studies.
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Figure 1: PRISMA flow charts with details of publications retrieved via searches, abstracts screened, full text 
articles assessed and used in analyses 
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Figure 2: (a) Forest plot demonstrating ORMS for HLA+EBNAhi persons. 
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Figure 2: (b) Forest plot demonstrating ORMS for HLA+EBNAlo persons. 
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Figure 2: (c) Forest plot demonstrating ORMS for HLA-EBNAhi persons. 
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(d) Bar chart demonstrating evidence of interaction between HLA-DRB1*1501 genotype and EBNA antibody 
titre on an additive, but not multiplicative scale. The dotted line represents the null (OR = 1) 
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. (e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
Page 35 of 83
http://mc.manuscriptcentral.com/multiple-sclerosis
Multiple Sclerosis Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
. (e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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(e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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(e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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(a) Forest plot of studies examining the relationship between previous infectious mononucleosis  and MS. 
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(b) Funnel plot demonstrating no clear evidence of publication bias in these studies. 
203x203mm (300 x 300 DPI) 
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(c) Forest plot demonstrating ORMS for HLA+IM+ persons. 
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(d) Forest plot demonstrating ORMS for HLA+IM- persons. 
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(e) Forest plot demonstrating ORMS for HLA-IM+ persons. 
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(f) Bar chart demonstrating lack of evidence of interaction between HLA-DRB1*1501 genotype and prior IM 
on an additive, but not multiplicative scale. The dotted line represents the null (OR = 1). 
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(g) - (j) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
The reference group (with OR = 1) is HLA-IM-  individuals for all panels. 
Page 45 of 83
http://mc.manuscriptcentral.com/multiple-sclerosis
Multiple Sclerosis Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
(g) - (j) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
The reference group (with OR = 1) is HLA-IM-  individuals for all panels. 
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(g) - (j) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
The reference group (with OR = 1) is HLA-IM-  individuals for all panels. 
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(g) - (j) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
The reference group (with OR = 1) is HLA-IM-  individuals for all panels. 
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Figure 4: (a) Forest plot demonstrating ORMS for EBNAhiSmoking+ persons. 
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(b) Forest plot demonstrating ORMS for EBNAhiSmoking- persons. 
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(c) Forest plot demonstrating ORMS for EBNA-Smoking+ persons. 
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(d) Bar chart demonstrating lack of evidence of interaction between smoking status and EBNA titre on an 
additive, but not multiplicative scale. 
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(e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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(e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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(e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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(e) - (h) Forest plots demonstrating estimates of interaction - AP, RERI, Synergy index, and multiplicative 
interaction respectively - for studies with individual-level data available. MIT: Multiplicative interaction term. 
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: (a) Combined forest plot with meta-analysis of EBV seropositivity in children and adults with MS. Odds 
ratios represent the odds ratio for EBV seropositivity given a diagnosis of MS (i.e. odds of EBV seropositivity 
among people with MS / odds of EBV seropositivity among controls). 
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(b) Funnel plot demonstrating evidence of publication bias in publications examining EBV seropositivity and 
MS 
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Table S1: interaction effect estimates for interaction between HLA status and EBNA titre – 
subgroup analysis based on method of HLA genotyping.
 PCR-based HLA genotyping
Estimate SE P.value
AP 0.600626 0.080903 1.14E-13
RERI 5.848862 1.473361 7.20E-05
Log(Synergy index) 0.8520740 0.29822258 4.274305e-03
Multiplicative 
interaction
1.771796 1.030103 0.453711
Tag SNP HLA genotyping
Estimate SE P.value
AP 0.148602 0.209132 0.477353
RERI 0.988962 1.947507 0.611587
Log(Synergy index) 0.1139513 0.2786410 0.6825735
Multiplicative 
interaction
0.446705 1.320622 0.675241
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Table S2: interaction effect estimates for interaction between smoking status and EBNA titre 
– subgroup analysis with one study excluded due to second-hand smoke exposure being used 
as the exposure, and one for using serum cotinine as a proxy measure for smoking. 
Excluding study assessing second-hand smoke
Estimate SE P.value
AP 0.188255 0.127964 0.14125
RERI 0.39963 0.372714 0.283623
Log(Synergy index) 0.2422447 0.2503367 0.3332064
Multiplicative 
interaction
1.179697 0.781378 0.818112
Excluding study using cotinine as proxy for smoking
Estimate SE P.value
AP 0.159765 0.158914 0.314724
RERI 0.377317 0.477298 0.429221
Log(Synergy index) 0.1489028 0.2585146 0.5646194
Multiplicative 
interaction
1.263166 0.888417 0.767063
Page 60 of 83
http://mc.manuscriptcentral.com/multiple-sclerosis
Multiple Sclerosis Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Supplementary figure legends
Supplementary figure 1: (a)-(d) Graphs as per figure 2, analysis restricted to studies using 
tagging SNPs to determine HLA genotype. (e) - (h)  Graphs as per figure 2, analysis 
restricted to studies using PCR-based methods to determine HLA genotype.
Supplementary figure 2: (a)-(d) Graphs as per figure 3, analysis restricted to studies using 
tagging SNPs to determine HLA genotype. (e) - (h)  Graphs as per figure 3, analysis 
restricted to studies using PCR-based methods to determine HLA genotype.
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Supplementary References
References for EBV seropositivity and MS
(i) Adults: 
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][2
5][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][4
7][48]
(ii) Paediatric MS
[49][50][51][52][53][54][55][56][57][58]
References for IM and MS
[59][60][61][16][28][62][63][64][65][66][67][68][69][70][71][72][73][74][75]
References examining EBV DNA detectable by PCR
[2][76][25][37][44][77][78][79][80][81][82][83][84][85][86][87][88][89]
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